Takeda announces EMA approval for Takhzyro two mL pre-filled pen option
Takeda (TAK) announced that the EMA has approved an additional two mL pre-filled pen option for Takhzyro for subcutaneous administration in ...
CAPLYTA’S Strong Market Adoption Propels Its Rise As A Leading Antipsychotic Therapy | Delveinsight
Intra-Cellular Therapies' CAPLYTA is making waves in the antipsychotic market, gaining traction as a novel treatment for schizophrenia and bipolar de ...
BofA highlights top Japanese stock picks after strong Q3 earnings
Investing.com-- Bank of America (BofA) analysts highlighted several Japanese stocks as top picks following strong ...